aim
describ
potenti
benefit
new
rapid
molecular
respiratori
test
mrt
decreas
inappropri
antibiot
use
among
inpati
present
influenzalik
ill
ili
includ
patient
inpati
outpati
depart
ili
perform
mrt
januari
decemb
privat
hospit
istanbul
end
implement
antimicrobi
stewardship
includ
systemat
use
mrt
compar
observ
year
year
design
studi
accord
strengthen
report
observ
studi
epidemiolog
strobe
tool
us
food
drug
administr
fda
clear
multiplex
polymeras
chain
reaction
pcr
system
biofir
filmarray
idaho
technolog
salt
lake
citi
ut
detect
virus
three
bacteria
use
diagnosi
total
patient
includ
inpati
older
year
age
least
one
viru
detect
patient
rhinovirusenteroviru
influenza
viru
adenoviru
commonli
detect
among
hospit
patient
children
signific
decreas
antibiot
use
p
observ
adult
decreas
statist
signific
p
durat
antibiot
use
detect
viru
significantli
decreas
children
adult
p
p
respect
use
mrt
inappropri
antibiot
use
also
durat
inappropri
antibiot
use
detect
viru
significantli
decreas
time
increas
awar
viral
etiolog
respiratori
tract
infect
rti
implement
mrt
clinic
practic
respiratori
tract
infect
rti
common
reason
admiss
healthcar
facil
one
lead
caus
hospit
viral
pathogen
etiolog
rti
becam
detect
along
improv
molecular
diagnost
method
recent
year
adult
influenza
viru
rhinoviru
adenoviru
respiratori
syncyti
viru
rsv
human
coronaviru
parainfluenza
viru
caus
infect
consider
morbid
mortal
infant
rsv
common
reason
rti
among
hospit
patient
antibiot
prescript
rate
report
despit
high
proport
viral
etiolog
unnecessari
antibiot
administr
viral
infect
antimicrobi
resist
prompt
implement
antimicrobi
stewardship
am
program
bimplement
antibiot
stewardship
programguidelin
infecti
diseas
societi
america
idsa
suggest
rapid
viral
test
respiratori
pathogen
decreas
inappropri
antibiot
use
studi
aim
describ
viral
etiolog
influenzalik
ill
ili
children
adult
show
benefit
new
rapid
molecular
respiratori
test
mrt
decreas
inappropri
antibiot
use
design
studi
accord
strengthen
report
observ
studi
epidemiolog
strobe
tool
includ
consequ
patient
inpati
outpati
depart
moder
sever
ili
therefor
need
diagnost
evalu
januari
decemb
privat
hospit
istanbul
patient
mrt
implement
diagnosi
includ
studi
mrt
introduc
hospit
demand
mrt
increas
year
end
enhanc
train
antimicrobi
stewardship
am
intervent
consist
train
physician
increas
awar
mrt
highlight
antimicrobi
resist
unnecessari
antibiot
consumpt
ad
hoc
meet
relat
depart
compar
observ
year
year
retrospect
studi
perform
review
patient
chart
clinic
featur
patient
demograph
characterist
chronic
diseas
includ
malign
disord
diabet
mellitu
chronic
kidney
liver
diseas
detail
inform
antibiot
antivir
drug
hospit
collect
chart
review
complet
blood
count
creactiv
protein
liver
kidney
function
test
studi
among
patient
bacteri
cultur
throat
sputum
blood
urin
obtain
procalcitonin
pct
studi
patient
suspicion
bacteri
infect
andor
critic
patient
chest
xray
lung
comput
tomographi
done
lower
respiratori
tract
infect
lrti
suspect
ili
defin
accord
world
health
organ
explain
acut
respiratori
infect
fever
cough
onset
within
last
day
inappropri
antibiot
use
defin
antibiot
use
despit
detect
viru
without
document
andor
suspici
bacteri
infect
antibiot
use
durat
calcul
durat
antibiot
use
detect
viru
patient
inappropri
antibiot
use
molecular
detect
identif
respiratori
viral
pathogen
us
food
drug
administr
fda
clear
multiplex
respiratori
polymeras
chain
reaction
pcr
system
mrt
biofir
filmarray
idaho
technolog
salt
lake
citi
ut
detect
viral
respiratori
pathogen
adenoviru
coronaviru
coronaviru
coronaviru
coronaviru
hmpv
rhinovirusenteroviru
influenza
influenza
influenza
influenza
influenza
b
parainfluenza
parainfluenza
parainfluenza
parainfluenza
rsv
three
bacteria
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
use
accord
manufactur
instruct
mrt
yield
result
within
hour
result
immedi
report
physician
patient
laboratori
staff
statist
analysi
ttest
continu
variabl
chisquar
test
comparison
categor
variabl
use
analysi
stata
statacorp
colleg
station
tx
use
pvalu
set
total
patient
mrt
implement
includ
inpati
older
year
age
least
one
viru
detect
patient
inpati
fig
fig
patient
multipl
viral
pathogen
detect
overal
rate
lrti
among
inpati
among
inpati
infect
rsv
rate
lrti
adult
children
similarli
hmpv
infect
rate
lrti
adult
children
tabl
total
among
hospit
patient
antibiot
continu
inappropri
tabl
children
antibiot
continu
rate
decreas
p
adult
decreas
toward
signific
tabl
mean
durat
inappropri
antibiot
use
detect
viru
decreas
adult
children
compar
commonli
inappropri
use
antibiot
thirdgener
cephalosporin
quinolon
secondgener
cephalosporin
studi
rhinovirusenteroviru
influenza
adenoviru
commonli
detect
virus
etiolog
ili
recent
studi
jain
et
al
populationbas
surveil
communityacquir
pneumonia
among
adult
age
year
older
conduct
human
rhinoviru
influenza
b
viru
hmpv
commonli
detect
virus
etiolog
influenza
viru
rhinoviru
report
commonli
detect
virus
adult
children
turkey
among
inpati
older
year
age
lrti
influenza
rhinoviru
rsv
hmpv
common
agent
among
children
lrti
rhinoviru
rsv
hmpv
common
agent
fig
fig
commonli
detect
virus
among
patient
least
one
viru
detect
rsv
respiratori
syncyti
viru
hmpv
human
metapneumoviru
tabl
effort
target
reduc
unnecessari
use
antibiot
viral
pneumonia
could
use
era
antibiot
resist
high
rate
inappropri
antibiot
prescript
despit
avail
mrt
decid
improv
train
session
diagnosi
manag
respiratori
system
infect
end
perform
observ
comparison
practic
decreas
antibiot
use
toward
among
inpati
howev
analyz
separ
signific
reduct
children
adult
detect
tabl
signific
reduct
antibiot
use
children
adult
could
explain
differ
physician
experi
mrt
despit
fact
reduct
antibiot
use
children
detect
viru
antibiot
prescript
rate
still
high
recent
studi
impact
mrt
antibiot
use
investig
seen
antibiot
still
continu
patient
despit
detect
viru
find
explain
new
test
anoth
studi
afzal
et
al
report
posit
result
mrt
decreas
antibiot
use
durat
prescript
rate
decreas
antibiot
prescript
statist
signific
timbrook
et
al
studi
mrt
combin
pct
conclud
lower
level
pct
detect
viru
mrt
associ
decreas
use
antibiot
rti
anoth
studi
lower
level
pct
combin
detect
viru
found
associ
shorten
durat
antibiot
usag
random
control
studi
effect
mrt
pct
antibiot
use
evalu
durat
antibiot
use
found
decreas
case
viral
infect
lower
level
pct
one
strongest
part
studi
opportun
order
mrt
whenev
need
routin
clinic
practic
reach
larg
sampl
size
opportun
get
result
creactiv
protein
pct
mrt
within
hour
discrimin
bacteri
viral
etiolog
quickli
one
limit
studi
conduct
singl
center
center
uniqu
implement
test
clinic
practic
uniqu
mrt
still
expens
perform
routin
clinic
practic
hospit
futur
studi
rapid
pointofcar
test
respiratori
virus
might
improv
clinic
care
reduc
unnecessari
antibiot
use
futur
costeffect
studi
implement
mrt
use
use
molecular
rapid
test
mrt
hospit
inappropri
antibiot
use
also
durat
inappropri
antibiot
use
detect
viru
significantli
decreas
among
inpati
treatment
paradigm
respiratori
tract
infect
rti
chang
molecular
viral
diagnost
test
infanc
time
increas
awar
viral
etiolog
rti
implement
mrt
clinic
practic
fund
fund
kind
receiv
data
gener
part
routin
work
conflict
interest
none
declar
ethic
approv
univers
irb
approv
studi
inform
consent
applic
mean
durat
inappropri
antibiot
use
day
sd
sd
sd
sd
